Patient-derived CD19- and CD22 specific CAR clinical trials

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

This study looks at a new treatment for certain types of leukaemia and lymphoma that have come back or not responded to usual treatments. It uses specially modified cells from the patient to target and fight cancer cells more effectively.